FDA

Malaria drug brings new hope for glioblastoma patients

4794 3196 Anna Stelling, PhD

Glioblastoma is a very aggressive form of cancer. Even though there is a low number of patients who live longer than 5 years after diagnosis – a statistic that researchers…

read more
Brainwork-stroke-rates

FDA warns of high stroke rates using artificial heart system

1920 1080 Peter Stevenson, PhD

The Food and Drug Administration (FDA) in the U.S. has published a letter warning surgeons and cardiologists of high stroke and mortality rates associated with the Temporary Total Artificial Heart…

read more

FDA approves blockbuster migraine treatment

1200 800 Mea Holm, PhD

On May 17th, 2018, the US FDA approved Aimovig™ (erenumab) following successful phase III trials. Aimovig™, co-developed by Amgen and Novartis, is the first approved migraine treatment targeting the calcitonin gene…

read more

First MS treatment approved for children & adolescents

1600 1067 Peter Stevenson, PhD

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10 to 18 years with relapsing…

read more

Impressive results for a new vaccine

1600 1076 Camilla Norrmén, PhD

Experts are enthusiastic about a new shingles vaccine that received FDA approval last month. Shingrix is significantly more effective than the only currently available shingles vaccine and provides considerably longer…

read more
Brainwork is supported by unrestricted grants from: